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OVER 50% OF CHILDREN with lympho-
blastic leukaemia (ALL) will relapse and
die, many with no features to suggest
such a poor clinical outlook (Simone,
1980). There can be no confident predic-
tion ofresponse to treatment in any given
case, which raises the possibility that
impaired drug availability is the cause
of at least some therapeutic failures.
This idea is supported by the variable
pharmacokinetics observed with both oral
methotrexate (MTX) (Kearney et al.,
1979; Pinkerton et al., 1980) and steroids
(Lilleyman et al., 1981), and at least one
study has suggested that the apparent
variable bioavailability of drugs may be
due to non-compliance (Smith et al.,
1979).
The main use of 6-mercaptopurine
(6-MP) in the treatment of ALL is to
prolong the duration ofremission achieved
with other drugs, and its cytotoxic effect
is considered to be due to intracellular
nucleotide metabolites. As we. had noted
very high red blood cell (RBC) concen-
trations of 6-thioguanine (6-TG) nucleo-
tide, a metabolite of both 6-MP and
azathioprine, in a patient who developed
severe myelosuppresion whilst taking
azathioprine, we speculated that measure-
ment of this nucleotide might be a useful
index of 6-MP bioavailability. We decided
to see whether the assay had any clinical
Accepted 10 March 1982
relevance in a group of children with
ALL in remission.
Fifteen unselected children with ALL
were studied. There were 10 boys and
5 girls aged 3-13 years. All had been on
remission maintenance therapy from 4
weeks to 3 years. Three children had
6-MP prescribed daily for 3 weeks out
of 4, the remainder took the drug con-
tinuously every day. In both schedules
the starting dose was 75 mg/M2. In all
cases, 6-MP doses were adjusted to 75%,
50% or 0% of the schedule dose on a slid-
ing scale in the face of neutropenia or
thrombocytopenia at the time ofprescrip-
tion. Concurrently all received a single
dose of 20 mg/M2 of oral MTX weekly,
subject to similar dose adjustments, and
pulses of prednisone or prednisolone for
5 days every 4th or 6th week, coupled
with a single infusion of vincristine.
When the patient was not receiving
continuous 6-MP therapy, blood samples
were obtained in the final week of a 6-MP
treatment course. Blood samples (0.5 ml)
were taken just before a dose of 6-MP
and, when possible, at the time of vene-
puncture for vincristine therapy. Other-
wise, full parental consent was obtained.
Assay of RBC 6-TG nucleotide used a
technique originally developed to study
azathioprine metabolism in renal-trans-
plant recipients, and will be published in6-MERCAPTOPURINE IN ALL
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detail elsewhere. Briefly, the nucleotide
was extracted from 100 ,A of packed
RBCs, containing about 8 x 108 cells,
by a modification of the 6-thioinosinic
acid assay ofFletcher & Maddocks (1980),
and hyprolysed to the parent purine,
6-thioguanine, which was then assayed
fluorimetrically (Dooley & Maddocks,
1980). The amount of 6-TG nucleotide
was stated as ng of free 6-TG released
on hydrolysis of the nucleotide.
Statistical analysis was by Pearson's
product-moment correlation coefficient.
RBC concentrations of 6-TG nucleotide
alongside the prescribed 6-MP daily dose
for the preceding 7 days, and the total
dose for the preceding month are shown
in the Table, together with the corres-
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FIG. 1.-Relationship between RBC 6-TG
nucleotide concentration and the absolute
neutrophil count (ANC) 2 weeks later in
10 children treated with 6-MP and with an
ANC G 1-5 x 109/1 (r=-0-832. P<0-OOl.
n= 151.
139S. HERBER ET AL.
100-
90-
80-
E
E 70
, 60
50
40
0
*.
0
*
0 0 0
0 10 20
Absolute neutrophit count (week 2 )
30
( x109/l 1
Ffa. 2.-6-MP dose in mg/M2 plotte(d against
the ANC 2 weeks later.
ponding neutrophil count at the time of
assay and 2 weeks later.
There was a statistically significant
correlation between the RBC concentra-
tion of 6-TG nucleotide and the absolute
peripheral neutrophil count 2 weeks later.
For the group as a whole, r= 0-61, P < 0 01
(n = 22), but when children with neutro-
penia were studied (absolute neutrophil
count (ANC) < 1U5 x 1091-1) the correlation
was stronger, r= -0-832, P < 0 001 (n=
15). This is shown in Fig. 1.
On the other hand, there was no
correlation at all between the dose of
6-MP, whether expressed as total dose
for the preceding month, the daily dose
for the preceding week or the dose at the
time of assay, and the absolute neutrophil
count, either at that time or 2 weeks
later (Fig. 2), nor was there any correlation
between RBC concentrations of 6-TG
nucleotide and these doses. Additionally,
there was no correlation between 6-TG
nucleotide levels and the length of time
the children had been taking 6-MP,
suggesting that the drug did not eventu-
ally impair its own metabolism.
Although we have no information on
intermediate absorption and metabolism
of6-MP, it seems likely that in the patients
studied RBC 6-TG nucleotide content is
a product of the drug, and relates to its
biological effect but not to the prescribed
oral dose. If so, the assay is clearly poten-
tiallv useful in monitoring the adequacy
of treatment with 6-MP. Unlike MTX,
which has peaks and troughs of serum
levels following each dose within a 24h
period, it seems that in patients taking
6-MP on a regular basis there is a slow
build up of RBC 6-TG nucleotide, and the
fall on stopping the drug takes days and
weeks rather than hours. This characteris-
tic makes a single random assay useful,
in that it probably reflects the meta-
bolism of a whole course of treatment
rather than a single dose.
Currently, in children with leukaemia,
doses are adjusted on the basis of the
absolute neutrophil count (ANC) at the
time of prescription. The fact that we
could find no correlation whatever between
doses of 6-MP (even as the total for the
preceding month), and the ANC (at the
time or 2 weeks later) suggests this prac-
tice to be at best insensitive as a means
of monitoring drug levels. Unless the dose
is pushed to the point of inducing con-
tinuous myelosuppression, it is likely
that a negligible therapeutic effect could
result from a prescription based on body-
surface area. Using the ANC, there is a
strong tendency among clinicians to
underdose leukaemic children to avoid
profound neutropenia and all its un-
pleasant sequelae. There is no converse
tendency to increase the dose above a
standard level ifthe ANC remains normal.
Using an assay system such as this,
however, it might be possible to identify
those children failing to achieve an ade-
quate response to 6-MP, whether this is
due to defective absorption, transport,
accelerated metabolism or even com-
pliance. This may be highly relevant to
their ultimate chances of long survival,
and help to indicate why some children
inexplicably do better than others. Too
little attention has been paid to pharmaco-
kinetics in these disorders, and studies
like ours raise many more questions than
they answer.
We wishl to thank the AI.R.C. for financial suipport
to L.L.
1(0
I140
.
. .6-MERCAPTOPURINE IN ALL 141
REFERENCES
DOOLEY, T. & MADDOCKS, J. L. (1980) Assay of
6-thioguanine in human plasma. Br. J. Clin
Pharmacol. 9. 77.
FLETCHER, L. & MADDOCKS, J. L. (1980) Assay of
thioinosinic acid, an active metabolite of azathio-
prine, in human lymphocytes. Br. J. Clin. Pharm-
acol., 10, 287.
KEARNEY, P. J., LIGHT, P. A., PREECE, A. & MOTT,
M.G. (1979) Unpredictable serum levels after
oral methotrexate in children with acute lympho-
blastic leukaemia. Cancer Chemother. Pharmacol.,
3, 117.
LILLEYMAN, J. S., FRENCH, A. J. & YouNG, C. P.
(1981) Variation in 17 oxogenic steroid excretion
following oral prednisolone in children with
lymphoblastic leukaemia. Oncology, 38, 274.
PINKERTON, C. R., WELSHMAN, S. G., GLASGOW,
J. F. T. & BRIDGES, J. M. (1980) Can food
influence the absorption of methotrexate in
children with acute lymphoblastic leukaemia.
Lancet, ii, 944.
SIMONE, J. V. (1980) The treatment ofacute lympho-
blastic leukaemia. Br. J. Haematol., 45, 1.
SMITH, S. D., ROSEN, D., TRUEWORTH, R. C. &
LOWMAN, J. T. (1979) A reliable method for
evaluating drug compliance in children with
cancer. Cancer, 43, 169.